Q-omics provides the consensus-scored BSNDP2 profile across patient tissues and cancer cell-line models. BSNDP2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, BSNDP2 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, BSNDP2 RNA expression shows 11,919 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, LIHC, and THYM as cancer lineages where BSNDP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BSNDP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BSNDP2 survival associations across molecular data types. BSNDP2 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BSNDP2 RNA expression–survival associations across cancer types. High BSNDP2 expression shows unfavorable associations in UCEC, KIRC and COAD, but favorable associations in UVM, ESCA and OV. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .010). Together, the overview and detailed table identify UCEC as the clearest survival context for BSNDP2 RNA expression.
This table summarizes BSNDP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for BSNDP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BSNDP2 shows lower tumor expression in THCA and higher tumor expression in LIHC, UCEC, READ, LUAD and LUSC. The LIHC box plot shows higher BSNDP2 RNA expression in tumor versus normal tissue (log2 FC = +0.047, t-test p = .009).
This table shows molecular features associated with BSNDP2 in patient tissues and cancer cell lines. In patient samples, BSNDP2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
